Develops integrin-based drug candidates for people with solid tumors and builds a platform for delivering medicines to specific tissues.
10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is…View ↗
Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in…View ↗
Since our founding, we have built a drug discovery platform that today consists of a proprietary library of over 15,000 integrin binding…View ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
−$24.4MView ↗
8-K, filed Mar 30, 2026
As previously disclosed, on March 30, 2026, Pliant Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, or the 2026 Sales…View ↗
From fibrosis to oncology
The earlier report centered the business on fibrosis candidates for lung and liver disease, including bexotegrast. The latest report centers its lead program on a solid-tumor candidate and describes drug delivery and a broader integrin platform.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 11, 2026We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is…View ↗
Our wholly owned lead product candidate, PLN-101095, is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins in…View ↗
Since our founding, we have built a drug discovery platform that today consists of a proprietary library of over 15,000 integrin binding…View ↗
Competes with AbbVie, Bicara Therapeutics, CatalyM, Corbus Pharmaceuticals, Incyte, IO Biotech, Keros Therapeutics, Oncotelic Therapeutics, Pfizer, Roche/Genetech, Scholar Rock, and Sirnaomics
10-K for FY2025, filed Mar 11, 2026Companies that compete with us directly on the level of commercialization or development of product candidates targeting various parts of…View ↗
Loading...